Full Text Journal Articles in
Journal Eur Urol

Advertisement

Find full text journal articles






Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.

Andrew J Vickers,

<h4>Background</h4>It has been suggested that targeting prostate lesions identified on magnetic resonance imaging (MRI) will improve the sensitivity of prostate biopsy for high-grade disease. The clinical significance of high-grade tumors found on MRI but missed on systematic biopsy is open to question.<h4>Objective</h4>To determine the risk of mortality for high-grade cancers ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium.

Sarah P Psutka, Todd Morgan, Maarten Albersen, Jean-Nicolas Cornu, Giacomo Novara, Elizabeth Plimack, Piet Ost, James W F Catto,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Addressing Equality of Representation in Urology Societies.

Christopher R Chapple, Peter Albers, John Denstedt,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men.

Karl H Pang, Christopher R Chapple, Robin Chatters, Alison P Downey, Christopher K Harding, Daniel Hind, Nick Watkin, Nadir I Osman,

<h4>Context</h4>Urethral stricture disease (USD) is initially managed with minimally invasive techniques such as urethrotomy and urethral dilatation. Minimally invasive techniques are associated with a high recurrence rate, especially in recurrent USD. Adjunctive measures, such as local drug injection, have been used in an attempt to reduce recurrence rates.<h4>Objective</h4>To systematically review ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.

Gerhardt Attard, Louise C Brown, Noel W Clarke, Mahesh K B Parmar, Nicholas D James,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.

Cora N Sternberg, Daniel Castellano, Johann de Bono, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Theodore, Susan Feyerabend, Carole Helissey, Elizabeth M Poole, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Ronald de Wit,

<h4>Background</h4>In the CARD study (NCT02485691), cabazitaxel significantly improved median radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received docetaxel and progressed ≤12 mo on the alternative agent (abiraterone/enzalutamide).<h4>Objective</h4>To assess cabazitaxel versus abiraterone/enzalutamide in older (≥70 yr) and younger ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Infant Robot-assisted Laparoscopic Pyeloplasty: Outcomes at a Single Institution, and Tips for Safety and Success.

Ciro Andolfi, Veronica M Rodríguez, Logan Galansky, Mohan S Gundeti,

<h4>Background</h4>Since its first description, multiple reports proved efficacy and safety of the robotic platform. Further progress has been made allowing for the application of robotic surgery to smaller patients, including infants. Despite the early favorable results, the use of robot surgery in infants is still controversial and more studies are ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.

Stéphane Supiot, Loig Vaugier, David Pasquier, Xavier Buthaud, Nicolas Magné, Didier Peiffert, Paul Sargos, Gilles Crehange, Pascal Pommier, Genevieve Loos, Ali Hasbini, Igor Latorzeff, Marlon Silva, Fabrice Denis, Jean-Léon Lagrange, Cyrille Morvan, Loic Campion, Audrey Blanc-Lapierre,

<h4>Background</h4>Oligorecurrent pelvic nodal relapse in prostatic cancer is a challenge for regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in metastatic prostate cancer, and salvage pelvic radiotherapy may offer long ADT-free intervals for patients harboring regional nodal relapses.<h4>Objective</h4>To assess the efficacy of the combination of ADT and salvage ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



When Less is More for Postprostatectomy Salvage Radiotherapy.

Sophia C Kamran,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy.

Herjan J T Coelingh Bennink, Jean-Michel Foidart, Frans M J Debruyne,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses.

Teresa Marsden, Hashim U Ahmed, Mark Emberton, ,

ReIMAGINE represents the first efforts to define prostate cancer risk using the full spectrum of emerging diagnostics (both commercial and academic). The outputs will provide image-based data sets that will replace, or adjust, historical and flawed risk calculators. ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Defining Resistance to Immune Checkpoint Inhibitors in Urothelial Carcinoma: Insights from PURE-01.

Timothy N Clinton,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Richard T. Bryan, Wenyu Liu, Sarah J. Pirrie, et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol 2021;80:12-5.

Henglong Hu,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

Arnaud Méjean, Alain Ravaud, Simon Thezenas, Christine Chevreau, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwenaelle Gravis, Frederic Rolland, Claude Linassier, Eric Lechevallier, Stephane Oudard, Brigitte Laguerre, Marine Gross-Goupil, Jean Christophe Bernhard, Sandra Colas, Laurence Albiges, Thierry Lebret, Jean-Marc Treluyer, Marc-Olivier Timsit, Bernard Escudier,

<h4>Background</h4>The CARMENA trial in patients with metastatic renal cell carcinoma (mRCC) demonstrated that treatment with sunitinib alone was noninferior to cytoreductive nephrectomy (CN) followed by sunitinib (nephrectomy-sunitinib).<h4>Objective</h4>The objective of this study was to provide updated overall survival (OS) outcomes of CARMENA and assess whether some subgroups may still benefit from ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?

Swayamjeet Satapathy, Namrata Das, Ashwani Sood, Shikha Goyal, Renu Madan, Bhagwant R Mittal,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review.

Ricardo Leão, Maarten Albersen, Leendert H J Looijenga, Torgrim Tandstad, Christian Kollmannsberger, Matthew J Murray, Stephane Culine, Nicholas Coleman, Gazanfer Belge, Robert J Hamilton, Klaus-Peter Dieckmann,

<h4>Context</h4>Clinical management of testicular germ cell tumours (GCTs) is hampered by low sensitivity and specificity of the biomarkers currently in use. Circulating microRNAs (miRs) might offer the potential to address areas of unmet clinical need.<h4>Objective</h4>To systematically evaluate the evidence for clinical applications of serum levels of miR302/367 and miR371-3 in ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction.

Andrea Salonia, Carlo Bettocchi, Luca Boeri, Paolo Capogrosso, Joana Carvalho, Nusret Can Cilesiz, Andrea Cocci, Giovanni Corona, Kostantinos Dimitropolous, Murat Gül, Georgios Hatzichristodoulou, T Hugh Jones, Ates Kadioglu, Juan Ignatio Martínez Salamanca, Uros Milenkovic, Vaibhav Modgil, Giorgio Ivan Russo, Ege Can Serefoglu, Tharu Tharakan, Paolo Verze, Suks Minhas, ,

<h4>Context</h4>The present summary of the European Association of Urology (EAU) guidelines is based on the latest guidelines on male sexual health published in March 2021, with a last comprehensive update in January 2021.<h4>Objective</h4>To present a summary of the 2021 version of the EAU guidelines on sexual and reproductive health.<h4>Evidence acquisition</h4>A ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study.

Girish S Kulkarni,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.

Vidit Sharma, R Jeffrey Karnes,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort.

Christoph Würnschimmel, Randi Marisa Pose, Mike Wenzel, Zhe Tian, Reha-Baris Incesu, Pierre Karakiewicz, Markus Graefen, Derya Tilki,

The proposed international staging collaboration for cancer of the prostate (STAR-CAP) clinical prognostic system for prostate cancer predicts cancer-specific mortality (CSM) for patients for whom active treatment, such as radical prostatectomy (RP), is planned. Until now, no validation of STAR-CAP has been performed. We retrospectively analyzed data from our institutional ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.

Scott Wilkinson, Huihui Ye, Rosina T Lis, Adam G Sowalsky,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Primary Renal Tumour Response to Immunotherapy: Lessons from Metastatic Disease and Insights into Earlier Settings.

Laura Marandino, Andrea Necchi,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.02.031.

Rachel M Glicksman, Alejandro Berlin,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.

Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.

Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, Daniel R Zwahlen, Tobias Hölscher, Philipp Gut, Bülent Polat, Guido Hildebrandt, Arndt-Christian Müller, Ludwig Plasswilm, Alexandros Papachristofilou, Corinne Schär, Marcin Sumila, Kathrin Zaugg, Matthias Guckenberger, Piet Ost, Christiane Reuter, Davide G Bosetti, Kaouthar Khanfir, Silvia Gomez, Peter Wust, George N Thalmann, Daniel M Aebersold, ,

<h4>Background</h4>Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP).<h4>Objective</h4>To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT.<h4>Design, setting, and participants</h4>SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP.<h4>Intervention</h4>Patients were randomly assigned ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0182 s